148 related articles for article (PubMed ID: 27642336)
1. Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®.
Naderi M; Karimi M; Hosseini MS; Moradi EH; Shamsizadeh M; Dorgalaleh A
Iran J Pharm Res; 2016; 15(2):635-40. PubMed ID: 27642336
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.
Naderi M; Dorgalaleh A; Alizadeh S; Tabibian S; Hosseini S; Shamsizadeh M; Bamedi T
Int J Hematol; 2014 Nov; 100(5):443-9. PubMed ID: 25230816
[TBL] [Abstract][Full Text] [Related]
3. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study.
Nugent D
Thromb Res; 2012 Dec; 130 Suppl 2():S12-4. PubMed ID: 23439001
[TBL] [Abstract][Full Text] [Related]
4. Massive recurrent post-tonsillectomy bleedings revealing a transient factor XIII deficiency in a 10-year-old boy. A case report.
Jankovic M; Choucair ML; Hallak B; Hernandez E; Russo M; Llor J; Kayemba-Kay's S
Int J Pediatr Adolesc Med; 2019 Jun; 6(2):55-57. PubMed ID: 31388547
[TBL] [Abstract][Full Text] [Related]
5. Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation.
Naderi M; Ahmadinejad M; Hosseini MS; Moradi E; Dorgalaleh A; Shamsizadeh M
Blood Coagul Fibrinolysis; 2017 Jun; 28(4):276-278. PubMed ID: 27306330
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study.
Lusher J; Pipe SW; Alexander S; Nugent D
Haemophilia; 2010 Mar; 16(2):316-21. PubMed ID: 20017752
[TBL] [Abstract][Full Text] [Related]
7. A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran.
Naderi M; Haghpanah S; Miri-Aliabad G; Tavosi H; Karimi M
J Thromb Haemost; 2017 Dec; 15(12):2300-2305. PubMed ID: 29028293
[TBL] [Abstract][Full Text] [Related]
8. Intracranial Hemorrhage: A Devastating Outcome of Congenital Bleeding Disorders-Prevalence, Diagnosis, and Management, with a Special Focus on Congenital Factor XIII Deficiency.
Alavi SER; Jalalvand M; Assadollahi V; Tabibian S; Dorgalaleh A
Semin Thromb Hemost; 2018 Apr; 44(3):267-275. PubMed ID: 28898896
[TBL] [Abstract][Full Text] [Related]
9. Factor XIII deficiency in Iran: a comprehensive review of the literature.
Dorgalaleh A; Naderi M; Hosseini MS; Alizadeh S; Hosseini S; Tabibian S; Eshghi P
Semin Thromb Hemost; 2015 Apr; 41(3):323-9. PubMed ID: 25615432
[TBL] [Abstract][Full Text] [Related]
10. Blood coagulation factor XIII and factor XIII deficiency.
Dorgalaleh A; Rashidpanah J
Blood Rev; 2016 Nov; 30(6):461-475. PubMed ID: 27344554
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of factor XIII deficiency.
Dorgalaleh A; Tabibian S; Hosseini MS; Farshi Y; Roshanzamir F; Naderi M; Kazemi A; Zaker F; Aghideh AN; Shamsizadeh M
Hematology; 2016 Aug; 21(7):430-9. PubMed ID: 27077776
[TBL] [Abstract][Full Text] [Related]
12. First cases of severe congenital factor XIII deficiency in Southwestern Afghanistan in the vicinity of southeast of Iran.
Hosseini S; Dorgalaleh A; Bamedi T; Tavakol K; Tabibian S; Naderi M; Alizadeh S; Varmaghani B; Shamsizadeh M; Rahimizadeh A; Ebrahimi S
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):908-11. PubMed ID: 26226252
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Ashley C; Chang E; Davis J; Mangione A; Frame V; Nugent DJ
Haemophilia; 2015 Jan; 21(1):102-8. PubMed ID: 25377187
[TBL] [Abstract][Full Text] [Related]
14. Factor XIII deficiency diagnosis: Challenges and tools.
Karimi M; Peyvandi F; Naderi M; Shapiro A
Int J Lab Hematol; 2018 Feb; 40(1):3-11. PubMed ID: 29027765
[TBL] [Abstract][Full Text] [Related]
15. Intracranial hemorrhage pattern in the patients with factor XIII deficiency.
Naderi M; Zarei T; Haghpanah S; Eshghi P; Miri-Moghaddam E; Karimi M
Ann Hematol; 2014 Apr; 93(4):693-7. PubMed ID: 24149912
[TBL] [Abstract][Full Text] [Related]
16. A Unique Factor XIII Mutation in Southeastern Iran with an Unexpectedly High Prevalence: Khash Factor XIII.
Dorgalaleh A; Tabibian S; Shams M; Majid G; Naderi M; Casini A; Tavasoli B; Gheidishiran M; Daneshi M; Safa M
Semin Thromb Hemost; 2019 Feb; 45(1):43-49. PubMed ID: 30630205
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for laboratory diagnosis of factor XIII deficiency.
Dorgalaleh A; Tabibian S; Hosseini S; Shamsizadeh M
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):361-4. PubMed ID: 26588445
[TBL] [Abstract][Full Text] [Related]
18. Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures.
Janbain M; Nugent DJ; Powell JS; St-Louis J; Frame VB; Leissinger CA
Transfusion; 2015 Jan; 55(1):45-50. PubMed ID: 25070582
[TBL] [Abstract][Full Text] [Related]
19. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
[TBL] [Abstract][Full Text] [Related]
20. Successful long-term replacement therapy with FXIII concentrate (Fibrogammin(®) P) for severe congenital factor XIII deficiency: a prospective multicentre study.
Dreyfus M; Barrois D; Borg JY; Claeyssens S; Torchet MF; Arnuti B; Pautard B;
J Thromb Haemost; 2011 Jun; 9(6):1264-6. PubMed ID: 21481176
[No Abstract] [Full Text] [Related]
[Next] [New Search]
